MGAT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19750110	0.50	4/20
SCHEMBL14111931	0.52	3/20
SCHEMBL14111938	0.50	3/20
SCHEMBL13551623	0.47	3/20
SCHEMBL5369910	0.41	3/20
SCHEMBL7493556	0.52	2/20
SCHEMBL7493564	0.52	2/20
SCHEMBL7495325	0.49	2/20
SCHEMBL7499102	0.48	2/20
SCHEMBL7499109	0.48	2/20
SCHEMBL31388425	0.47	2/20
SCHEMBL7136606	0.45	2/20
SCHEMBL14111925	0.45	2/20
SCHEMBL7136121	0.44	2/20
SCHEMBL7136258	0.44	2/20
SCHEMBL7495963	0.43	2/20
SCHEMBL7495974	0.43	2/20
SCHEMBL5361704	0.42	2/20
SCHEMBL5363038	0.41	2/20
SCHEMBL24152344	0.39	2/20

Clinical trials — most relevant to MGAT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3	PHASE3	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List	PHASE2	WITHDRAWN
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Oral OKT3 in Combination With Beta-D-Glucosylceramide	PHASE1	UNKNOWN
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands	PHASE1	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Alpha -1- Microglobulin (α1M) as an Early Biomarker in Renal Extrahepatic Manifestations of HCV-infection	nan	UNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)	nan	UNKNOWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Effect of an Polyphenolic Beverage in Healthy Volunteers	nan	ACTIVE_NOT_RECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Effect of Migalastat on Cardiac Involvement in Fabry Disease	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism	nan	COMPLETED
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)	nan	RECRUITING
Chest Wall Deformities in Children - Epidemiological Data	nan	COMPLETED
Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes	nan	COMPLETED
1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus	nan	COMPLETED
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MGAT1 binder may also engage these)

Protein	Name	Similarity
Q09325	—	1.000	Q09325 →
P27115	—	0.999	P27115 →
P27808	—	0.998	P27808 →
Q5QQ49	—	0.978	Q5QQ49 →
Q5U309	—	0.977	Q5U309 →
Q00973	—	0.976	Q00973 →
Q9EPI0	—	0.976	Q9EPI0 →
Q66PG4	—	0.975	Q66PG4 →
A3KGW5	—	0.975	A3KGW5 →
Q09200	—	0.974	Q09200 →
Q8N3Y3	—	0.974	Q8N3Y3 →
Q5T4B2	—	0.974	Q5T4B2 →
Q5XPT3	—	0.974	Q5XPT3 →
Q9H1B5	—	0.973	Q9H1B5 →
Q5QQ51	—	0.972	Q5QQ51 →
A0JPH3	—	0.971	A0JPH3 →
Q10468	—	0.971	Q10468 →
Q811B1	—	0.971	Q811B1 →
Q6PA90	—	0.970	Q6PA90 →
Q8IYK4	—	0.970	Q8IYK4 →
A5PMF6	—	0.970	A5PMF6 →
Q6P1J0	—	0.969	Q6P1J0 →
Q5QQ56	—	0.968	Q5QQ56 →
Q6NVG7	—	0.968	Q6NVG7 →
Q9EPL0	—	0.968	Q9EPL0 →
Q8NBI6	—	0.968	Q8NBI6 →
Q8JGM4	—	0.967	Q8JGM4 →
Q5R9N3	—	0.967	Q5R9N3 →
Q5QQ50	—	0.967	Q5QQ50 →
Q5DTK1	—	0.966	Q5DTK1 →